AIMS: The aim of this study was to investigate the efficiency of adenoviral-mediated transfer of the interleukin (IL)-10 gene for inhibition of experimental autoimmune anterior uveitis, a rat model of human acute anterior uveitis. Uveitis was induced in the Lewis rat by simultaneous injection of melanin-associated antigen intraperitoneally (i.p.) and into the left footpad. The animals were treated by systemic administration of adenoviral construct expressing IL-10 (Ad-IL-10) or Ad-Mock carrying no cytokine transgene. RESULTS: A significant reduction in ocular inflammation was noted for rats that received one or two divided i.p. administrations of Ad-IL-10 (one 10 x 10(9) and two 5 x 10(9) particles of adenoviral construct, respectively), as judged by reduced clinical scores and decreased leukocyte infiltration in the anterior chamber and confirmed by histological examinations, relative to control animals. Systemic Ad-IL-10, treatment also revealed a higher serum level of IL-10, compared to the controls. CONCLUSIONS: The results suggest that systemic adenovirus-mediated IL-10 gene therapy has an anti-inflammatory effect on immune-mediated ocular inflammation and that this approach may be promising for the treatment of acute anterior uveitis.
AIMS: The aim of this study was to investigate the efficiency of adenoviral-mediated transfer of the interleukin (IL)-10 gene for inhibition of experimental autoimmune anterior uveitis, a rat model of humanacute anterior uveitis. Uveitis was induced in the Lewis rat by simultaneous injection of melanin-associated antigen intraperitoneally (i.p.) and into the left footpad. The animals were treated by systemic administration of adenoviral construct expressing IL-10 (Ad-IL-10) or Ad-Mock carrying no cytokine transgene. RESULTS: A significant reduction in ocular inflammation was noted for rats that received one or two divided i.p. administrations of Ad-IL-10 (one 10 x 10(9) and two 5 x 10(9) particles of adenoviral construct, respectively), as judged by reduced clinical scores and decreased leukocyte infiltration in the anterior chamber and confirmed by histological examinations, relative to control animals. Systemic Ad-IL-10, treatment also revealed a higher serum level of IL-10, compared to the controls. CONCLUSIONS: The results suggest that systemic adenovirus-mediated IL-10 gene therapy has an anti-inflammatory effect on immune-mediated ocular inflammation and that this approach may be promising for the treatment of acute anterior uveitis.
Authors: Shivaram Selvam; Padmaja B Thomas; Sarah F Hamm-Alvarez; Joel E Schechter; Douglas Stevenson; Austin K Mircheff; Melvin D Trousdale Journal: Adv Drug Deliv Rev Date: 2006-09-15 Impact factor: 15.470
Authors: P Trittibach; S E Barker; C A Broderick; M Natkunarajah; Y Duran; S J Robbie; J W B Bainbridge; A J Smith; G-M Sarra; A D Dick; R R Ali Journal: Gene Ther Date: 2008-06-26 Impact factor: 5.250
Authors: Elizabeth Crabtree; Katy Uribe; Sara M Smith; Darby Roberts; Jacklyn H Salmon; Jacquelyn J Bower; Liujiang Song; Prabhakar Bastola; Matthew L Hirsch; Brian C Gilger Journal: PLoS One Date: 2022-08-18 Impact factor: 3.752
Authors: Elizabeth Crabtree; Liujiang Song; Telmo Llanga; Jacquelyn J Bower; Megan Cullen; Jacklyn H Salmon; Matthew L Hirsch; Brian C Gilger Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379